Pressmeddelanden från Novo Nordisk

Bevaka pressreleaser

Kurs från TradingView

Start Nyheter Pressreleaser Riktkurser Insynshandel Blankning Analyser Bloggar Videos Podcasts

Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026 12 maj 16:49

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons 12 maj 12:25

Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity 12 maj 08:00

Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity 06 maj 07:31

Novo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026 05 maj 12:43

Novo Nordisk A/S - share repurchase programme 28 apr 14:00

Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity 27 apr 10:56

Novo Nordisk A/S - share repurchase programme 23 apr 11:10

Novo Nordisk’s oral semaglutide demonstrates potential to be the first oral GLP-1 RA therapy for children and adolescents with type 2 diabetes 20 apr 14:32

Novo Nordisk A/S - share repurchase programme 20 apr 11:19

Novo Nordisk: Etavopivat is the first in a new class of drugs to meet both co-primary endpoints in the phase 3 HIBISCUS trial, substantially reducing vaso-occlusive crisis events and improving haemoglobin response in sickle cell disease 14 apr 08:00

Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered 13 apr 12:36

Novo Nordisk A/S - share repurchase programme 09 apr 14:28

Novo Nordisk A/S: Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU 07 apr 12:46

Novo Nordisk A/S – Share repurchase programme 30 mar 13:49

Novo Nordisk A/S - share repurchase programme 27 mar 11:23

Articles of Association for Novo Nordisk A/S 2026 27 mar 00:36

Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes 26 mar 16:15

Resolutions from the Annual General Meeting of Novo Nordisk A/S 25 mar 07:00

Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes 23 mar 13:19

Novo Nordisk A/S - share repurchase programme 19 mar 16:40

Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss 16 mar 10:56

Novo Nordisk A/S - share repurchase programme 09 mar 11:39

Novo Nordisk A/S - share repurchase programme 02 mar 16:55

Election of employee representatives to the Board of Directors of Novo Nordisk A/S 02 mar 12:22

Novo Nordisk A/S - share repurchase programme 02 mar 10:00

Novo Nordisk announces more than 400 million euro expansion in its manufacturing facility in Athlone, Ireland 25 feb 14:00

Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes 24 feb 09:39

Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China 23 feb 13:24

Novo Nordisk A/S - share repurchase programme 23 feb 10:33

Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved 20 feb 13:02

Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S 17 feb 14:58

Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy® for adults with obesity; clinical study showed people lost about 21% of their body weight on average 16 feb 13:21

Novo Nordisk A/S - share repurchase programme 11 feb 21:14

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons 10 feb 10:17

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons 09 feb 13:16

Novo Nordisk A/S - share repurchase programme 09 feb 12:59

Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy® and Ozempic®05 feb 19:50

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons 05 feb 16:46

Novo Nordisk issues statement on illegal mass compounding and deceptive advertising by Hims & Hers 04 feb 15:53

Novo Nordisk files annual report with the SEC 04 feb 08:00

Novo Nordisk initiates 2026 share repurchase programme 04 feb 07:30

Novo Nordisk has published its annual report for 2025 03 feb 17:38

Novo Nordisk's sales increased by 6% in Danish kroner and by 10% at constant exchange rates to DKK 309.1 billion in 2025 03 feb 17:37

Novo Nordisk releases 2026 sales and operating profit outlook 02 feb 16:43

Novo Nordisk A/S: CagriSema demonstrated superior HbA1c reduction of 1.91%-points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial 31 jan 08:00

New employee representative on the Board of Directors of Novo Nordisk A/S 20 jan 14:30

Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes 31 dec 2025 14:24

Novo Nordisk A/S: China’s Supreme People’s Court delivers a positive ruling on the semaglutide compound patent 22 dec 2025 23:50

Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management 12 dec 2025 14:57

Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss 09 dec 2025 14:51

Novo Nordisk has completed its acquisition of Akero Therapeutics 25 nov 2025 12:24

Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes 24 nov 2025 12:21

Novo Nordisk A/S: Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression 17 nov 2025 14:58

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons 14 nov 2025 15:21

Resolutions from the Extraordinary General Meeting of Novo Nordisk A/S 13 nov 2025 23:38

Novo Nordisk A/S: Candidate for the Board of Directors will not seek election 11 nov 2025 14:40

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons 08 nov 2025 09:19

Novo Nordisk will not increase its proposal to acquire Metsera, Inc. 06 nov 2025 19:01

Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost 05 nov 2025 22:30

Novo Nordisk Wegovy® users achieved waist and BMI targets linked to improved health and low risk of obesity-related complications 05 nov 2025 07:30

Novo Nordisk's sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues 04 nov 2025 15:31

Novo Nordisk submits updated proposal to acquire Metsera, Inc.30 okt 2025 10:49

Novo Nordisk submits proposal to acquire Metsera, Inc.21 okt 2025 14:02

Notice convening an Extraordinary General Meeting of Novo Nordisk A/S 21 okt 2025 13:56

Novo Nordisk announces an Extraordinary General Meeting to be convened to elect new members of the Board of Directors 15 okt 2025 14:30

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)09 okt 2025 12:00

Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio 18 sep 2025 10:45

Novo Nordisk A/S: Ozempic® reduces the risk of heart attack, stroke and death by 23% compared to dulaglutide in the first head-to-head real-world study 17 sep 2025 23:05

Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study 16 sep 2025 12:00

Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme 16 sep 2025 00:03

People taking Novo Nordisk’s Wegovy® experienced reduced food noise and boosted mental well-being 15 sep 2025 14:00

EU approval makes Novo Nordisk’s oral semaglutide the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke 05 sep 2025 08:01

Novo Nordisk to present new semaglutide data on ‘food noise’, body composition and cardiovascular benefits, as well as pipeline data at the EASD diabetes congress 31 aug 2025 09:09

Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease 20 aug 2025 15:31

Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025 19 aug 2025 13:37

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons 15 aug 2025 23:23

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH 12 aug 2025 14:26

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons 08 aug 2025 15:16

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons 07 aug 2025 17:31

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons 06 aug 2025 07:30

Novo Nordisk's sales increased by 16% in Danish kroner and by 18% at constant exchange rates to DKK 154.9 billion in the first six months of 2025 29 jul 2025 13:36

Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk 29 jul 2025 13:02

Novo Nordisk lowers sales and operating profit outlook for 2025 25 jul 2025 12:47

European regulatory authority adopts positive opinion for Novo Nordisk’s Alhemo® (concizumab), recommending label expansion to treat haemophilia A and B without inhibitors 23 jun 2025 20:36

Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities 22 jun 2025 21:35

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress 22 jun 2025 15:00

Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine 21 jun 2025 01:38

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA 21 jun 2025 01:34

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025 12 jun 2025 19:06

Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development 10 jun 2025 14:00

ADA 2025: Novo Nordisk highlights strong portfolio data with new semaglutide and CagriSema results, redefining possibilities in obesity and diabetes care 16 maj 2025 13:19

Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk 16 maj 2025 13:02

Novo Nordisk A/S: Lars Fruergaard Jørgensen to step down as CEO of Novo Nordisk 14 maj 2025 12:59

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases 12 maj 2025 08:01

Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE 09 maj 2025 13:22

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons 07 maj 2025 07:30

Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025 06 maj 2025 14:00

Novo Nordisk A/S: ECO 2025 - Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases 03 apr 2025 08:00

Novo Nordisk announces changes in Executive Management